Ongoing trials with trastuzumab in metastatic breast cancer

Annals of Oncology

Volumn 12, Issue SUPPL. 1, 2001, Pages

  Bell, R ^a  

^a Andrew Love Cancer Centre   (Australia)

Author keywords

Docetaxel; Epirubicin; Herceptin; Metastatic breast cancer; Paclitaxel; Trastuzumab

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; EUROPE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; METASTASIS; MULTICENTER STUDY; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034873274     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/12.suppl_1.S69     Document Type: Article

References (6)

1. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
2. Overall survival (OS) advantage to Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
3. Addition of Herceptin® (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational III trial
4. First-line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
5. Weekly Herceptin + 1 hour Taxol: Phase II study in HER2 overexpressing and non-overexpressing metastatic breast cancer
6. Phase II trial of docetaxel and Herceptin as first- or second-line chemotherapy for women with metastatic breast cancer whose tumors overexpress HER2